OncoSec Medical Incorporated (ONCS) Shares Down 8.4%
OncoSec Medical Incorporated (NASDAQ:ONCS) dropped 8.4% during mid-day trading on Monday . The company traded as low as $1.16 and last traded at $1.20. Approximately 1,443,409 shares traded hands during trading, an increase of 458% from the average daily volume of 258,877 shares. The stock had previously closed at $1.31.
ONCS has been the subject of a number of recent research reports. Maxim Group reissued a “buy” rating and set a $5.00 price objective on shares of OncoSec Medical in a research report on Tuesday, October 10th. ValuEngine downgraded shares of OncoSec Medical from a “sell” rating to a “strong sell” rating in a research report on Monday, October 2nd. Finally, Dawson James reissued a “buy” rating and set a $5.00 price objective on shares of OncoSec Medical in a research report on Thursday, July 6th. One investment analyst has rated the stock with a sell rating and five have issued a buy rating to the stock. OncoSec Medical has a consensus rating of “Buy” and a consensus target price of $5.33.
The stock’s market cap is $25.40 million. The firm’s 50-day moving average price is $1.01 and its 200-day moving average price is $1.07.
About OncoSec Medical
OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company’s lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation.
Receive News & Stock Ratings for OncoSec Medical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical Incorporated and related stocks with our FREE daily email newsletter.